Evidence map›Paper›PMID 32453746›Full record

ArticlePloS one2020

Cross-sectional prevalence study of MERS-CoV in local and imported dromedary camels in Saudi Arabia, 2016-2018.

Ahmed M Tolah, Saad B Al Masaudi, Sherif A El-Kafrawy, Ahmed A Mirza, Steve M Harakeh, Ahmed M Hassan, Mohammed A Alsaadi, Abdulrahman A Alzahrani, Ghaleb A Alsaaidi, Nabil M S Amor and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. MERS-COV in the Middle East, a one health concept approach.One health (Amsterdam, Netherlands) · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ahmed M TolahKing Fahd Medical Research Center, Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Saad B Al MasaudiDivision of Microbiology, Department of Biological Science, Faculty of science, King Abdulaziz University, Jeddah, Saudi Arabia.
Sherif A El-KafrawyKing Fahd Medical Research Center, Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Ahmed A MirzaDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-5751-1667
Steve M HarakehKing Fahd Medical Research Center, Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Ahmed M HassanKing Fahd Medical Research Center, Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammed A AlsaadiKing Fahd Medical Research Center, Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Abdulrahman A AlzahraniDirectorate of Agriculture, Ministry of Environment Water and Agriculture, Makkah Region, Saudi Arabia.
Ghaleb A AlsaaidiDirectorate of Agriculture, Ministry of Environment Water and Agriculture, Makkah Region, Saudi Arabia.
Nabil M S AmorKSU Mammals Research Chair, Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Abdulaziz N AlagailiKSU Mammals Research Chair, Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Anwar M HashemKing Fahd Medical Research Center, Vaccines and Immunotherapy Unit, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-8471-7011
Esam I AzharKing Fahd Medical Research Center, Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-1736-181X
King Abdulaziz University · SAKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) is an endemic virus in dromedaries. Annually, Saudi Arabia imports thousands of camels from the Horn of Africa, yet the epidemiology of MERS-CoV in these animals is largely unknown. Here, MERS-CoV prevalence was compared in imported African camels and their local counterparts. A total of 1399 paired sera and nasal swabs were collected from camels between 2016 and 2018. Imported animals from Sudan (n = 829) and Djibouti (n = 328) were sampled on incoming ships at Jeddah Islamic seaport before unloading, and local camels were sampled from Jeddah (n = 242). Samples were screened for neutralizing antibodies (nAbs) and MERS-CoV viral RNA. The overall seroprevalence was 92.7% and RNA detection rate was 17.2%. Imported camels had higher seroprevalence compared to resident herds (93.8% vs 87.6%, p <0.01) in contrast to RNA detection (13.3% vs 35.5%, p <0.0001). Seroprevalence significantly increased with age (p<0.0001) and viral RNA detection rate was ~2-folds higher in camels <2-year-old compared to older animals. RNA detection was higher in males verses females (24.3% vs 12.6%, p<0.0001) but seroprevalence was similar. Concurrent positivity for viral RNA and nAbs was found in >87% of the RNA positive animals, increased with age and was sex-dependent. Importantly, reduced viral RNA load was positively correlated with nAb titers. Our data confirm the widespread of MERS-CoV in imported and domestic camels in Saudi Arabia and highlight the need for continuous active surveillance and better prevention measures. Further studies are also warranted to understand camels correlates of protection for proper vaccine development.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCamelusCoronavirus InfectionsCross-Sectional StudiesDisease ReservoirsDjiboutiFemaleMaleMiddle East Respiratory Syndrome CoronavirusPrevalenceRNA, ViralSaudi ArabiaSeroepidemiologic StudiesSudanAntibodies, NeutralizingAntibodies, ViralRNA, Viral

Identifiers

PMID32453746
PMCPMC7250453
OpenAlexW3030336927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.